PharmaLogic to buy Lantheus’ CDMO unit and New Jersey manufacturing site
PharmaLogic Holdings announced a definitive agreement to purchase Lantheus Holdings’ contract development and manufacturing organization (CDMO) business together with its Springfield, New Jersey production facility. The deal creates a cross‑Atlantic CDMO platform for radiopharmaceuticals and includes a long‑term contract for PharmaLogic to produce lutetium‑177 dotatate for Lantheus. Financial terms were not disclosed and the transaction will close only after regulatory clearance and other customary conditions are satisfied.
Why it matters
The acquisition expands PharmaLogic’s manufacturing footprint in the United States, giving it a broader base to serve partners developing radioligand therapies. Lantheus will secure a reliable supplier for its newly approved lutetium‑177 dotatate, which could support continued revenue from that product.
Key facts
- 1PharmaLogic will acquire Lantheus’ CDMO business and the Springfield, New Jersey facility. prnewswire.com
- 2The purchase includes a long‑term supply agreement for lutetium‑177 dotatate. prnewswire.com
- 3The financial terms of the transaction were not disclosed. prnewswire.com
- 4The deal is subject to regulatory review and customary closing conditions. prnewswire.com
- 5Lantheus will provide transition services after closing, according to an SEC filing. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.